Sertraline-doxepine

From Psychiatrienet
Revision as of 14:20, 28 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Sertraline
Type Antidepressant
Group SSRI
links
Medscape Sertraline
PubChem 68617
PubMed Sertraline
Kompas (Dutch) Sertraline
Wikipedia Sertraline
Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin

Switch medication from sertraline to doxepin.[2] [3]

Nietinrijdenbord.png Stop sertraline
  • Before day 1: Gradually reduce dosage of sertraline to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • Day 1: Reduce dosage of sertraline to a dosage of 25 mg/ day
  • Day 8: Stop administration of sertraline
Eenrichtingbord.png Start doxepin

Caution is necessary.

  • Day 1: simultaneously start administration of doxepin in a low dosage of 25 mg/day.
  • Day 8: stop administration of sertraline and only continue administration of doxepin only. If necessary, increase dosage of doxepin.
  • "Start low, go slow" is not required, but caution is necessary.
Infobord.png More information
  • Sertraline dose-dependently slows the metabolism of doxepin via CYP2D6.
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.